Primary source: What is an Early Alert?
AVID Medical must quarantine all impacted convenience kits and has issued recommendations to customers to remove and discard specific sodium chloride ampules before continued use.
This alert highlights a significant safety risk related to specific medical devices and emphasizes the need for compliance with regulatory guidelines to prevent potential harm to patients.
Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.
The FDA has issued an Early Alert regarding potential high-risk issues associated with convenience kits from AVID Medical, which contain recalled sodium chloride ampules from Huons Co. Medical advice includes quarantining affected kits and implementing new labeling.
What changed: AVID Medical must quarantine all impacted convenience kits and has issued recommendations to customers to remove and discard specific sodium chloride ampules before continued use.
Why it matters: This alert highlights a significant safety risk related to specific medical devices and emphasizes the need for compliance with regulatory guidelines to prevent potential harm to patients.
Practical implication: Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.
Published from the regulator source ingestion pipeline after PV impact triage.
Companies must ensure compliance with the Irish language requirements and complete mandatory OMS registration before regulatory submissions to prevent delays.
Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.
Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.
Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.
